Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells $7,763,875.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total transaction of $7,763,875.00. Following the sale, the chief executive officer directly owned 8,808,533 shares in the company, valued at approximately $411,358,491.10. This represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

NASDAQ:TEM opened at $50.47 on Monday. The company has a market cap of $9.06 billion, a PE ratio of -29.34 and a beta of 3.64. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The company’s 50 day moving average is $48.73 and its two-hundred day moving average is $58.10.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The company had revenue of $348.12 million for the quarter, compared to the consensus estimate of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. Tempus AI’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.24) EPS. Analysts anticipate that Tempus AI, Inc. will post -1.35 EPS for the current year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus unveiled the next generation of Lens, its agentic AI platform for oncology drug development, which could strengthen its long-term growth story by making its data and AI tools more useful for biopharma customers. Article: Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
• Positive Sentiment: The company also introduced Preview, a new application designed to provide rapid preliminary insights before definitive diagnostic results arrive, potentially improving workflow efficiency and reinforcing Tempus’ precision-medicine platform. Article: Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
• Positive Sentiment: Tempus launched the PRECISION Challenge, opening its foundation-model work to a broader research community, which may help accelerate innovation and broaden interest in its AI platform. Article: Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Institutional Trading of Tempus AI

Several large investors have recently made changes to their positions in the business. JPL Wealth Management LLC acquired a new position in shares of Tempus AI in the 3rd quarter valued at $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $27,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI in the 3rd quarter valued at $38,000. Whittier Trust Co. lifted its stake in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after purchasing an additional 570 shares during the period. Finally, Lodestone Wealth Management LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at $42,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TEM. Robert W. Baird began coverage on shares of Tempus AI in a report on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective on the stock. Stifel Nicolaus set a $60.00 price objective on shares of Tempus AI in a report on Wednesday, February 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Tempus AI in a report on Wednesday, March 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.